BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Locatelli M, Buelli S, Pezzotta A, Corna D, Perico L, Tomasoni S, Rottoli D, Rizzo P, Conti D, Thurman JM, Remuzzi G, Zoja C, Morigi M. Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. J Am Soc Nephrol 2014;25:1786-98. [PMID: 24578132 DOI: 10.1681/ASN.2013050450] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
Number Citing Articles
1 Perico L, Conti S, Benigni A, Remuzzi G. Podocyte-actin dynamics in health and disease. Nat Rev Nephrol 2016;12:692-710. [PMID: 27573725 DOI: 10.1038/nrneph.2016.127] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 15.3] [Reference Citation Analysis]
2 Michelfelder S, Fischer F, Wäldin A, Hörle KV, Pohl M, Parsons J, Reski R, Decker EL, Zipfel PF, Skerka C, Häffner K. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018;29:1141-53. [PMID: 29335241 DOI: 10.1681/ASN.2017070738] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
3 Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C. Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. Clin J Am Soc Nephrol 2019;14:364-77. [PMID: 30674459 DOI: 10.2215/CJN.05830518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
4 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
5 Cheung V, Trachtman H. Hemolytic uremic syndrome: toxins, vessels, and inflammation. Front Med (Lausanne) 2014;1:42. [PMID: 25593915 DOI: 10.3389/fmed.2014.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
6 Reiser J, Altintas MM. Podocytes. F1000Res 2016;5:F1000 Faculty Rev-114. [PMID: 26918173 DOI: 10.12688/f1000research.7255.1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 12.7] [Reference Citation Analysis]
7 Duineveld C, Steenbergen EJ, Bomback AS, van de Kar NCAJ, Wetzels JFM. Treatment-resistant nephrotic syndrome in dense deposit disease: complement-mediated glomerular capillary wall injury? Pediatr Nephrol 2020;35:1791-5. [PMID: 32447506 DOI: 10.1007/s00467-020-04600-9] [Reference Citation Analysis]
8 Morigi M, Perico L, Corna D, Locatelli M, Cassis P, Carminati CE, Bolognini S, Zoja C, Remuzzi G, Benigni A, Buelli S. C3a receptor blockade protects podocytes from injury in diabetic nephropathy. JCI Insight 2020;5:131849. [PMID: 32161193 DOI: 10.1172/jci.insight.131849] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
9 Zhou L, Liu Y. Wnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease. Nat Rev Nephrol 2015;11:535-45. [PMID: 26055352 DOI: 10.1038/nrneph.2015.88] [Cited by in Crossref: 99] [Cited by in F6Publishing: 103] [Article Influence: 14.1] [Reference Citation Analysis]
10 Dennhardt S, Pirschel W, Wissuwa B, Daniel C, Gunzer F, Lindig S, Medyukhina A, Kiehntopf M, Rudolph WW, Zipfel PF, Gunzer M, Figge MT, Amann K, Coldewey SM. Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease. Front Immunol 2018;9:1459. [PMID: 29988557 DOI: 10.3389/fimmu.2018.01459] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Exeni RA, Fernandez-Brando RJ, Santiago AP, Fiorentino GA, Exeni AM, Ramos MV, Palermo MS. Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2018;33:2057-71. [PMID: 29372302 DOI: 10.1007/s00467-017-3876-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
12 Li L, Yin Q, Tang X, Bai L, Zhang J, Gou S, Zhu H, Cheng J, Fu P, Liu F. C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway. PLoS One 2014;9:e113639. [PMID: 25422985 DOI: 10.1371/journal.pone.0113639] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
13 Leffler J, Prohászka Z, Mikes B, Sinkovits G, Ciacma K, Farkas P, Réti M, Kelen K, Reusz GS, Szabó AJ, Martin M, Blom AM. Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome. J Innate Immun 2017;9:12-21. [PMID: 27784011 DOI: 10.1159/000450609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
14 Buelli S, Zoja C, Remuzzi G, Morigi M. Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms 2019;7:E15. [PMID: 30634669 DOI: 10.3390/microorganisms7010015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
15 Villysson A, Tontanahal A, Karpman D. Microvesicle Involvement in Shiga Toxin-Associated Infection. Toxins (Basel) 2017;9:E376. [PMID: 29156596 DOI: 10.3390/toxins9110376] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
16 Zheng JM, Wang SS, Tian X, Che DJ. Sustained activation of C3aR in a human podocyte line impairs the morphological maturation of the cells. Mol Med Rep 2020;22:5326-38. [PMID: 33174024 DOI: 10.3892/mmr.2020.11626] [Reference Citation Analysis]
17 Walsh PR, Johnson S. Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 2019;34:1485-92. [PMID: 30058046 DOI: 10.1007/s00467-018-4025-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Casiraghi F, Todeschini M, Azzollini N, Cravedi P, Cassis P, Solini S, Fiori S, Rota C, Karachi A, Carrara C, Noris M, Perico N, Remuzzi G. Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation 2019;103:1121-30. [PMID: 30801518 DOI: 10.1097/TP.0000000000002611] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Ozaki M, Kang Y, Tan YS, Pavlov VI, Liu B, Boyle DC, Kushak RI, Skjoedt MO, Grabowski EF, Taira Y, Stahl GL. Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injury. Kidney Int 2016;90:774-82. [PMID: 27378476 DOI: 10.1016/j.kint.2016.05.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
20 Brady TM, Pruette C, Loeffler LF, Weidemann D, Strouse JJ, Gavriilaki E, Brodsky RA. Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak. J Clin Exp Nephrol 2016;1:11. [PMID: 27413789 DOI: 10.21767/2472-5056.100011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
21 Feitz WJC, Bouwmeester R, van der Velden TJAM, Goorden S, Licht C, van den Heuvel LPJW, van de Kar NCAJ. The Shiga Toxin Receptor Globotriaosylceramide as Therapeutic Target in Shiga Toxin E. coli Mediated HUS. Microorganisms 2021;9:2157. [PMID: 34683478 DOI: 10.3390/microorganisms9102157] [Reference Citation Analysis]
22 Morigi M, Locatelli M, Rota C, Buelli S, Corna D, Rizzo P, Abbate M, Conti D, Perico L, Longaretti L, Benigni A, Zoja C, Remuzzi G. A previously unrecognized role of C3a in proteinuric progressive nephropathy. Sci Rep 2016;6:28445. [PMID: 27345360 DOI: 10.1038/srep28445] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
23 Lee MS, Tesh VL. Roles of Shiga Toxins in Immunopathology. Toxins (Basel) 2019;11:E212. [PMID: 30970547 DOI: 10.3390/toxins11040212] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
24 Caillaud C, Zaloszyc A, Licht C, Pichault V, Frémeaux-Bacchi V, Fischbach M. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-61. [PMID: 26399238 DOI: 10.1007/s00467-015-3207-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
25 Zoja C, Buelli S, Morigi M. Shiga toxin triggers endothelial and podocyte injury: the role of complement activation. Pediatr Nephrol 2019;34:379-88. [PMID: 29214442 DOI: 10.1007/s00467-017-3850-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]